Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy

SIMPLE SUMMARY: The efficacy and safety of the BNT126b2 vaccine against SARS-CoV-2 has not been thoroughly studied in cancer patients treated with immunotherapy. This research aims to investigate the efficacy and safety of the vaccine in patients with melanoma under immunotherapy; at the same time,...

Descripción completa

Detalles Bibliográficos
Autores principales: Diamantopoulos, Panagiotis T., Kontandreopoulou, Christina-Nefeli, Gkoufa, Aikaterini, Solomou, Elena, Anastasopoulou, Amalia, Palli, Eleni, Kouzis, Panagiotis, Bouros, Spyros, Samarkos, Mihalis, Magiorkinis, Gkikas, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367332/
https://www.ncbi.nlm.nih.gov/pubmed/35954454
http://dx.doi.org/10.3390/cancers14153791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367332/
https://www.ncbi.nlm.nih.gov/pubmed/35954454
http://dx.doi.org/10.3390/cancers14153791

Ejemplares similares